5-(1H-吡唑-3-基)-噻吩-2-羧酸甲酯 | 474707-59-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 5-(1H-吡唑-3-基)-噻吩-2-羧酸甲酯
• 英文名称: methyl 5-(1H-3-pyrazolyl)-2-thiophene-carboxylate
• 英文别名: 5-(1H-pyrazol-3-yl)-thiophene-2-carboxylic acid methyl ester；methyl 5-(1H-pyrazol-5-yl)thiophene-2-carboxylate
• CAS: 474707-59-0
• 化学式: C₉H₈N₂O₂S
• 分子量: 208.241
• InChiKey: FUEGCOHVINCFBO-UHFFFAOYSA-N

物化性质

• 沸点：
  434.4±35.0 °C(Predicted)
• 密度：
  1.355±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  83.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(1H-吡唑-3-基)-噻吩-2-羧酸甲酯 生成 methyl 5-(1-trityl-1H-3-pyrazolyl)-2-thiophene-carboxylate
  参考文献：
  名称：

  NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF

  摘要：

  公开号：

  EP1382603B1
• 作为产物：
  描述：

  5-乙酰基-噻吩-2-羧酸甲酯 生成 5-(1H-吡唑-3-基)-噻吩-2-羧酸甲酯
  参考文献：
  名称：

  NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF

  摘要：

  公开号：

  EP1382603B1

文献信息

• [EN] SUBSTITUTED THIENYL-HYDROXAMIC ACIDS AS HISTONE DEACETYLASE INHIBITORS<br/>[FR] ACIDES SUBSTITUES THIENYLHYDROXAMIQUES UTILISES EN TANT QU'INHIBITEURS D'HISTONE DESACETYLASE
  申请人：ARGENTA DISCOVERY LTD

  公开号：WO2004013130A1

  公开（公告）日：2004-02-12

  A compound of formula (I): which can be used in the treatment of diseases associated with histone deacetylase enzymatic activity.

  化合物的化学式（I）：可用于治疗与组蛋白去乙酰化酶活性相关的疾病。
• [EN] SUBSTITUTED THIENYL-HYDROXAMIC ACIDS HAVING HISTONE DEACETYLASE ACTIVITY<br/>[FR] ACIDES HYDROXAMIQUES DE THIENYLE SUBSTITUES PRESENTANT UNE ACTIVITE DE DEACETYLASE
  申请人：ARGENTA DISCOVERY LTD

  公开号：WO2005014588A1

  公开（公告）日：2005-02-17

  A compound of formula (I): in which A represents optionally substituted monocyclic heteroaryl or phenyl B represents optionally substituted heteroaryl, aryl, aryl-fused-heterocycloalkyl, heteroaryl-fused-cycloalkyl, heteroaryl-fused-heterocycloalkyl or aryl-fused-cycloalkyl X and Y, which may be the same or different, each independently represent -0-, -NR1-, CO-, -S02-, -SO-, -S-, -NR1CO-, -NR1S02-, -CONR1-, -SO2NR1-, -NR1CONR1 or X may be a direct bond when Y represents -NR1-, -NR1CO-, -NR1SO2-, -CONR1-, - SO2NR1- or -NR1CONRI- provided that R1 represents alkyl substituted by -OR2, -NR3R4, - NR4COR5, -NR4SO2R5, -CONR3R4 or -S02NR3R4 R1 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, or alkyl substituted by -OR2, -NR3R4, -NR4COR5, -NR4S02R5, -CONR3R4 or -S02NR3R4 R2 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl or cycloalkyl R3 represents H or alkyl R4 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl or cycloalkyl or NR3R4 represents a cyclic amine R5 represents alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl n represents 0-3 m represents 1-3 p represents 0-3 and corresponding N-oxides, pharmaceutically acceptable salts, solvates and prodrugs thereof; and use to treat a disease in which inhibition of histone deacetylase can prevent, inhibit or ameliorate the pathology and/or symptomatology of the disease.

  化合物的化学式（I）：其中A代表可选择取代的单环杂环芳基或苯基，B代表可选择取代的杂环芳基、芳基、芳基-融合-杂环烷基、杂环烷基-融合-环烷基、杂环烷基-融合-杂环烷基或芳基-融合-环烷基，X和Y，可以相同也可以不同，每个独立代表-0-、-NR1-、CO-、-SO2-、-SO-、-S-、-NR1CO-、-NR1SO2-、CONR1-、-SO2NR1-、-NR1CONR1或当Y代表-NR1-、-NR1CO-、-NR1SO2-、-CONR1-、-SO2NR1-或-NR1CONRI-时，X可以是直接键，条件是R1代表由-OR2、-NR3R4、NR4COR5、NR4SO2R5、CONR3R4或-S02NR3R4取代的烷基，R1代表H、烷基、芳基烷基、杂环芳基烷基、杂环烷基烷基、环烷基烷基或由-OR2、-NR3R4、-NR4COR5、-NR4S02R5、-CONR3R4或-S02NR3R4取代的烷基，R2代表H、烷基、芳基烷基、杂环芳基烷基、杂环烷基烷基、环烷基烷基、芳基、杂环芳基、杂环烷基或环烷基，R3代表H或烷基，R4代表H、烷基、芳基烷基、杂环芳基烷基、杂环烷基烷基、环烷基烷基、芳基、杂环芳基、杂环烷基或环烷基，或NR3R4代表环胺，R5代表烷基、芳基、杂环芳基、环烷基、杂环烷基、芳基烷基、杂环芳基烷基、环烷基烷基、杂环烷基烷基，n代表0-3，m代表1-3，p代表0-3，以及相应的N-氧化物、药学上可接受的盐、溶剂合物和前药；以及用于治疗一种可以通过抑制组蛋白去乙酰化酶来预防、抑制或改善疾病的病理和/或症状的疾病。
• NITROGENOUS FUSED&minus;RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF
  申请人：Eisai Co., Ltd.

  公开号：EP1382603A1

  公开（公告）日：2004-01-21

  The present invention provides a compound having an excellent inhibitory action on activation of STAT6 and a pharmaceutical composition thereof. Inparticular, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them. In the formula, X represents a nitrogen-containing condensed aromatic heterocyclic group such as imidazo[1,2-a]pyridine, benzimidazole, quinazoline, quinoline, or 2,1-benzisoxazole and has (R4)n as substituent groups; Y represents a C3-8 cycloalkyl group, C4-8 cycloalkenyl group, 5- to 14-membered non-aromatic heterocyclic group, C6-14 aromatic hydrocarbon cyclic group or 5- to 14-membered aromatic heterocyclic group; n in (R4)n is 0, 1, 2 or 3, and Z groups independently represent (1) hydrogen atom, (2) amino group, (3) halogen atom, (4) hydroxyl group, (5) nitro group, (6) cyano group, (7) azido group, (8) formyl group, (9) hydroxyamino group, (10) sulfamoyl group, (11) guanodino group, (12) oxo group, (13) C2-6 alkenyl group, (14) C1-6 alkoxy group, (15) C1-6 alkylhydroxyamino group, (16) halogenated C1-6 alkyl group, (17) halogenated C2-6 alkenyl group, (18) (i) C3-7cycloalkyl group, (ii) C3-7cycloalkenyl group, (iii) 5- to 14-membered non-aromatic heterocyclic group, each of which may have one or more substituent groups Q, or (19) formula -M1-M2-M3, R1 represents (1) hydrogen atom, (2) halogen atom, (3) hydroxyl group, (4) nitro group, (5) cyano group, (6) halogenated C1-6 alkyl group, (7) C2-6 alkyl group substituted with a hydroxyl or cyano group, (8) C2-6 alkenyl group, or (9) formula -L1-L2-L3, and R2 represents a hydrogen atom or a protecting group; and R3 represents a hydrogen atom, halogen atom, cyano group, amino group, C1-4 alkyl group or halogenated C1-4 alkyl group.

  本发明提供了一种对 STAT6 的活化具有极佳抑制作用的化合物及其药物组合物。特别是提供了由下式（I）代表的化合物、其盐或它们的水合物。 式中，X代表含氮缩合芳香杂环基团，如咪唑并[1,2-a]吡啶、苯并咪唑、喹唑啉、喹啉或2,1-苯并异噁唑，并有(R4)n作为取代基；Y代表C3-8环烷基、C4-8环烯基、5～14元非芳香杂环基团、C6-14芳香烃环基或5～14元芳香杂环基团；(R4)n 中的 n 是 0、1、2 或 3，Z 基团独立地代表：(1) 氢原子，(2) 氨基，(3) 卤素原子，(4) 羟基，(5) 硝基，(6) 氰基，(7) 叠氮基，(8) 甲酰基，(9) 羟基氨基、(10) 氨基磺酰基，(11) 氨基胍基，(12) 氧代基，(13) C2-6 烯基，(14) C1-6 烷氧基，(15) C1-6 烷基羟基氨基，(16) 卤代 C1-6 烷基，(17) 卤代 C2-6 烯基，(18) (i) C3-7 环烷基、(ii) C3-7 环烯基，(iii) 5-14 元非芳杂环基团，其中每个基团可有一个或多个取代基 Q，或 (19) 式-M1-M2-M3，R1 代表 (1) 氢原子，(2) 卤素原子，(3) 羟基、(4) 硝基，(5) 氰基，(6) 卤代 C1-6 烷基，(7) 被羟基或氰基取代的 C2-6 烷基，(8) C2-6 烯基，或 (9) 式-L1-L2-L3，R2 代表氢原子或保护基团；R3 代表氢原子、卤素原子、氰基、氨基、C1-4 烷基或卤代 C1-4 烷基。
• Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2048142A2

  公开（公告）日：2009-04-15

  The present invention provides a compound having an excellent inhibitory action on activation of STAT6 and a pharmaceutical composition thereof. In particular, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them. In the formula, the groups X,Y,Z,R1-R4 and n are defined as in claim 1.

  本发明提供了一种对 STAT6 的活化具有极佳抑制作用的化合物及其药物组合物。特别是提供了由下式（I）代表的化合物、其盐或它们的水合物。 式中，基团 X、Y、Z、R1-R4 和 n 的定义如权利要求 1 所述。
• Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors
  申请人：Archer Ann Janet

  公开号：US20060122234A1

  公开（公告）日：2006-06-08

  A compound of formula (I): which can be used in the treatment of diseases associated with histone deacetylase enzymatic activity.

  一种式（I）化合物：可用于治疗与组蛋白去乙酰化酶酶活性有关的疾病。